Glitazones improve insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator- activated receptor-γ (PPAR-γ). In addition to sensitizing cells to insulin, the PPAR-γ may affect bone. Thus, an increasing body of evidence suggests that genetic mutations in the PPAR-γ as well as treatment with glitazones affect skeletal tissue.


Bone Mineral Density Polycystic Ovary Syndrome Marrow Adipocyte Bone Marrow Adipocyte Breast Adipose Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998;13:371–382.CrossRefPubMedGoogle Scholar
  2. 2.
    Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-{gamma}2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143:2376–2384.CrossRefPubMedGoogle Scholar
  3. 3.
    Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226–1235.CrossRefPubMedGoogle Scholar
  4. 4.
    Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ. Activation of peroxisome proliferator-activated receptor {gamma} (ppar{gamma}) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007;148:903–911.CrossRefPubMedGoogle Scholar
  5. 5.
    Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung Ui, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPAR {gamma} insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Investig 2004;113:846–855.Google Scholar
  6. 6.
    Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324–3329.CrossRefPubMedGoogle Scholar
  7. 7.
    Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203–216.CrossRefPubMedGoogle Scholar
  8. 8.
    Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrisnology 2004;145:401–406.CrossRefGoogle Scholar
  9. 9.
    Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin Endocrinol Metab 2007;92:1305–1310.CrossRefPubMedGoogle Scholar
  10. 10.
    Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR, for the Health AaBCHAS. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349–3354.CrossRefPubMedGoogle Scholar
  11. 11.
    Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor {{gamma}} ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604–1608.PubMedGoogle Scholar
  12. 12.
    Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’Keefe M, Ghazzi MN. troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626–1632.CrossRefPubMedGoogle Scholar
  13. 13.
    Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Lars Rejnmark
    • 1
  1. 1.Medical DepartmentAarhus University HospitalDenmark

Personalised recommendations